|Publication number||USRE40259 E1|
|Application number||US 11/359,982|
|Publication date||Apr 22, 2008|
|Filing date||Dec 12, 1998|
|Priority date||Dec 31, 1997|
|Also published as||CA2316902A1, CA2316902C, DE69813896D1, DE69813896T2, EP1045830A1, EP1045830B1, US6306903, WO1999035125A1|
|Publication number||11359982, 359982, PCT/1998/8157, PCT/EP/1998/008157, PCT/EP/1998/08157, PCT/EP/98/008157, PCT/EP/98/08157, PCT/EP1998/008157, PCT/EP1998/08157, PCT/EP1998008157, PCT/EP199808157, PCT/EP98/008157, PCT/EP98/08157, PCT/EP98008157, PCT/EP9808157, US RE40259 E1, US RE40259E1, US-E1-RE40259, USRE40259 E1, USRE40259E1|
|Inventors||Paolo Pevarello, Mario Varasi, Patricia Salvati, Claes Post|
|Original Assignee||Newron Pharmaceuticals, S.P.A.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (53), Non-Patent Citations (61), Referenced by (14), Classifications (21), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
This appln is a 371 of PCT/EP98/08157 filed Dec. 12, 1998.
The present invention relates to novel and known alpha-aminoamide compounds, to a process for their preparation, to pharmaceutical composition containing them and to their use as therapeutic agents.
In particular, the compounds of the present invention are endowed with analgesic properties and are particularly useful for the treatment and alleviation of chronic and neuropathic pain.
Chronic and neuropathic pain are associated with prolonged tissue damage or injuries to the peripheral or central nervous system and result from a number of complex changes in nociceptive pathways.
Clinical manifestations of chronic pain include a sensation of burning or electric shock, feelings of bodily distortion, allodynia and hyperpathia.
Despite the large number of available analgesics, their use is limited by severe side effects and modest activity in some pain conditions. Therefore there is still a clear need to develop new compounds.
International applications WO 90/14334, WO 94/22808, WO 97/05111 and WO 97/05102 disclose substituted benzylaminopropionamide compounds active on the central nervous system and useful as anti-epileptic, anti-Parkinson, neuroprotective, antidepressant, antispastic and hypnotic agents.
The present invention is based on the finding that compounds known from the above-cited international applications and new ones, closely related thereto, have analgesic properties in mammals, including humans.
Accordingly, one object of the present invention is to provide the use of a compound of formula (I)
A —(CH2)m—, —(CH2)n— or —(CH2)v— chain may be a branched or straight chain. Alkyl and alkoxy groups may be branched or straight groups. Representative examples of C1-C4 alkyl groups include methyl, ethyl, n- and iso-propyl, n-, iso- sec- and tert-butyl.
Representative examples of C1-C4 alkoxy groups include methoxy and ethoxy.
A C3-C6 cycloalkyl group is for instance cyclopropyl, cyclopentyl or cyclohexyl, in particular cyclopentyl or cyclohexyl.
A halogen atom is fluorine, bromine, chlorine or iodine, in particular, chlorine or fluorine.
Pharmaceutically acceptable salts of the compounds of the invention include acid addition salts with inorganic, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acids or organic, e.g. acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic acids.
The compounds of formula (I) have asymmetric carbon atoms and therefore they can exist either as racemic mixtures or as individual optical isomers (enantiomers).
Accordingly, the present invention also include within its scope all the possible isomers and their mixtures and both the metabolites and the pharmaceutically acceptable bioprecursors (otherwise known as pro-drugs) of the compounds of formula (I).
Preferred compounds of formula (I) are those wherein
Examples of specific compounds of formula (I) are:
An aspect of this invention relates to a pharmaceutically composition having analgesic activity, in particular against chronic and neuropathic pain, comprising a compound of formula (I), as herein defined, as an active agent and a pharmaceutically acceptable salt thereof.
A further aspect of this invention relates to a method of treating a mammal, including humans, in need of an analgesic agent, said method comprising administering thereto an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Neuropathic and chronic pain conditions in a mammal can thus be alleviated and treated. Examples of pain conditions that can be treated by a compound of formula (I) include:
Another object of the present invention are the novel compounds of formula (IA)
The compounds of formula (IA) fall within the scope fo the compound of formula (I), as herein defined. Therefore all the definitions and biological properties stated above as to a compound of formula (I) apply also to a compound of formula (IA).
In particular, preferred compounds of formula (IA) are those wherein
Specific examples of compounds of formula (IA) are:
The compounds of formula (I) and (IA) and the pharmaceutically acceptable salts thereof can be obtained by well known processes as described in the above cited international applications. In particular, a compound of formula (IA) and the salts thereof can be obtained by a process comprising:
a) reacting a compound of formula (II)
wherein R10, R11, A and s are as defined above, with a compound of formula (III)
wherein R2, R3 and R4 are as defined above, in the presence of a reducing agent thus obtaining a compound of formula (IA) in which R1 is hydrogen; or b) reacting a compound of formula (IV)
wherein R2, R3, R4, R10, R11, A and s are as defined above, with a compound of formula (V) or (VI) in this latter case in the presence of a reducing agent
wherein W is a halogen atom; R′5 is C1-C4 alkyl and R″5 is hydrogen or C1-C3 alkyl, thus obtaining a compound of formula (IA) in which R1 is C1-C4 alkyl; and, if desired, converting a compound of formula (IA) into another compound of formula (IA) and/or, if desired, converting a compound of formula (IA) into a pharmaceutically acceptable salt and/or, if desired, converting a slat into a free compound.
All the processes described hereabove are analogy processes and can be carried out according to well known methods in organic chemistry.
A compound of formula (IV) is a compound of formula (IA) in which R1 is hydrogen.
The reaction of a compound of formula (II) with a compound of formula (III) to give a compound of formula (IA) or (IV) is a reductive amination reaction which can be carried out according to well known methods. According to a preferred embodiment of the invention it may be performed under nitrogen atmosphere, in a suitable organic solvent, such as an alcohol, e.g. a lower alkanol, in particular methanol, or in acetonitrile, at a temperature ranging from about 0° C. to about 40° C., in the presence of a reducing agent, the most appropriate being sodium cyanoborohydride.
Occasionally molecular sieves can be added to the reaction mixture for facilitating the reaction.
In a compound of formula (V) the halogen W is preferably iodine. The alkylation reaction of a compound of formula (IV) with a compound of formula (V) can be carried out in a suitable organic solvent, such as an alcohol, e.g. methanol, ethanol or isopropanol, in particular in ethanol, at a temperature ranging from about 0° C. to about 50° C.
The alkylation reaction of a compound of formula (IV) with an aldehyde of formula (VI) can be carried out in a suitable organic solvent, such as an alcohol, e.g. methanol, ethanol or acetonitrile in the presence of a suitable reducing agent, such as sodium cyanoborohydride, at a temperature ranging from about 0° C. to about 30° C.
A compound of formula (IA) can be converted, as stated above, into another compound of formula (IA) by known methods. Process-variant b) above may be regarded as an example of optional conversion of a compound of formula (IA) into another compound of formula (IA).
Also the optional salification of a compound of formula (IA) as well as the conversion of a salt into the free compound may be carried out by conventional methods.
The compounds of formula (II) and (III), (V) and (VI) are known compounds or can be obtained by known methods. When in the compounds of the present invention and in the intermediate-products thereof, groups are present, which need to be protected before submitting them to the hereabove illustrated reactions, they may be protected before being reacted and then deprotected according to methods well known in organic chemistry.
The compounds of formula (I), (IA) and the pharmaceutically acceptable salts thereof are hereinafter defined as “the compounds of the invention” or “the active agents of the invention”.
As stated above, the compounds of the invention are active as analgesic agents, as proven for instance by the fact that they have been found to be active in the formalin test.
Formalin test is a useful tool for obtaining neurogenic inflammation and continuous pain (Shibata et al, Pain, 38: 347-352, 1989).
Formalin produces a distinct biphasic response. The early phase seems to be caused predominantly by C-fibre activation due to peripheral stimulus, while the late phase appears to be dependent on the combination of an inflammatory reaction in the peripheral tissue and functional changes in the dorsal horn of the spinal cord. This functional changes seem to be initiated by the C-fibre barrage during the early phase (Tjolsen et al. Pain 51, 5-17, 1992). Substance P and bradykinin participate in the early phase, while histamine, serotonin, prostaglandins and bradykinin are involved in the late phase.
Male NMRI CD- 1 mice (22-25 g) were injected with 20 ml μl of 2.7% solution of formalin into the right hindpaw and placed immediately into observation chambers. The cumulative licking time of the injected paw was recorded in the acute phase (0-5 min) and in the chronic phase (30-40 min) of the nociceptive response of formalin.
The two representative compounds of the invention (S)-2-[4-(3- fluorobenzyloxy)benzylamino]-propanamide, methanesulfonate (internal code PNU 151774E) and (S)-[2-[4-(3-fluorobenzyloxy)benzylamino]-2-methyl-propanamide 2-[4 -( 3 -fluorobenzyloxy)benzylamino]- 2 -methyl-propanamide (internal code PNU 156654E) were administered 60 min before formalin injection at the doses of 7.5, 15.0, 30.0 and 60.0 mg/kg; po. Morphine (5 mg/kg; sc) was used as a positive standard. The activities data were analysed by Dunnett's t-test.
Locomotor Activity and Rotarod
The effects of these compounds on locomotor activity and rotarod (a test for evaluating motor co-ordination) were studied in order to exclude changes in these parameters as confounding factors in the evaluation of the formalin response. The locomotor activity test lasted 15 min. Five minutes after testing locomotor activity, the mice were put on the rotarod for 2 min and the number of mice falling within this time were counted.
Compounds PNU 151774E and PNU 156654E were tested at the doses of 7.5, 15.0, 30.0 and 60.0 mg/kg; po. The compounds were administered 60 min before locomotor activity test.
Compounds PNU 151774E and PNU 156654E dose-dependently reduced cumulative licking time in both phases of the formalin test (Table 1) demonstrating analgesic activity without any effect on locomotor or rotarod activity (Table 2).
Effects of PNU 151774E and PNU 156654E
in the formalin nociception test in mice
160.2 ± 2.6
74.8 ± 3.7
137.9 ± 2.4a
72.4 ± 2.4
87.9 ± 3.3a
64.3 ± 2.8b
79.4 ± 3.0a
56.9 ± 2.6a
63.1 ± 2.6a
38.1 ± 3.6a
119.4 ± 5.2
73.1 ± 6.0
108.4 ± 4.2
62.4 ± 3.6
79.7 ± 3.7a
42.1 ± 6.2a
60.0 ± 2.3a
37.7 ± 6.9a
44.4 ± 4.2a
17.3 ± 6.6a
a= p < 0.01;
b= p < 0.05
Effects of PNU 151774E and PNU 156654E
on locomotor activity and rotarod
(mean ± sem)
2653 ± 163
2908 ± 234
2795 ± 255
2347 ± 203
2240 ± 195
1976 ± 232
1966 ± 188
2110 ± 256
2272 ± 317
2119 ± 310
In view of their biological activity, the compounds of the invention are useful in mammals, including humans, as analgesic agents. In particular they are useful in treating pain associated with damage or permanent alteration of the peripheral or central nervous system, for example peripheral neuropathies, such as trigeminal neuralgia, postherapeutic neuralgia, diabetic neuropathy, raticulopathy glossopharyngeal neuralgia, and neuropathy secondary to metastatic infiltration, adiposis dolorosa, and burn pain; and central pain conditions following stroke, thalamic lesions and multiple sclerosis.
The conditions of a patient in need of an analgesic agent may thus be improved.
The compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion.
The dosage depends on the age, weight, conditions of the patient and on the administration route; for example, the dosage adopted for oral administration to adult humans e.g. for the representative compounds of the invention
The invention includes pharmaceutical compositions comprising a compound of formula (IA), as an active principle, in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent). The pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
For example, the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, destrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; desegregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes.
The liquid dispersion for oral administration may be e.g. syrups, emulsions and suspension.
The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
The suspension and the emulsion may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
The suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
The suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
The following examples illustrate but do not limit the invention.
To a solution of N-methylserinamide hydrochloride (2 g; 0.0129 mol), in methanol (40 ml), 2 g of powdered 3A molecular sieves are added; after stirring 15′ at room temperature, 0.65 g (0.0102 mol) of sodium cyanoborohydride are added in a single portion followed by 2.85 g (0.012 mol) of 4-(3-cyanobenzyloxy)benzaldehyde. The mixture is stirred for 2 hours at room temperature, then filtered and the residue after evaporation is separated by flash-chromatography on silica gel (eluant: chloroform 98: methanol 2: 30% NH4OH 0.2). 2.6 g (63%) of pure titled compound (m.p. 130-134° C.).
[α]D: +12.8 (c=1.25 AcOH)
With the usual methods of pharmaceutical technique, preparation can be made of capsules having the following composition:
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3549690||Jun 8, 1967||Dec 22, 1970||Ici Ltd||Carboxylic acid derivatives|
|US3576864||Jul 31, 1967||Apr 27, 1971||Ciba Ltd||(trifluoromethyl-phenyl)semicarbazines|
|US3658967||May 14, 1970||Apr 25, 1972||Ici Ltd||Carboxylic acid derivatives for lowering the concentration of triglycerides in the blood|
|US4049663 *||Apr 30, 1976||Sep 20, 1977||Allen & Hanburys Limited||Ethylene diamine derivatives|
|US4267354||Feb 4, 1980||May 12, 1981||E. R. Squibb & Sons, Inc.||Substituted amides having antiinflammatory activity and intermediates|
|US4311853||Jan 30, 1980||Jan 19, 1982||The Radiochemical Centre Limited||Selenium derivatives of thyroxine and tri-iodothyronine|
|US4513009||Apr 14, 1981||Apr 23, 1985||Societe Civile Bioprojet||Aminoacid derivatives and their therapeutic applications|
|US4631287||Apr 16, 1985||Dec 23, 1986||Usv Pharmaceutical Corp.||Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments|
|US4639468||Aug 23, 1985||Jan 27, 1987||Continental Pharma Inc.||Derivatives of glycinamide, their preparation and their use|
|US4725608||Nov 21, 1984||Feb 16, 1988||Fujisawa Pharmaceutical Co., Ltd.||Semicarbazide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same|
|US4725619||Jun 23, 1986||Feb 16, 1988||Usv Pharmaceutical Corporation||Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments|
|US4839369||Mar 13, 1986||Jun 13, 1989||Rorer Pharmaceutical Corporation||Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments|
|US4927835||Mar 1, 1989||May 22, 1990||Nippon Shinyaku Co., Ltd.||Acylphenol derivatives, useful as anti-inflammatory agents and pain suppressants|
|US4927836||Jun 29, 1988||May 22, 1990||Imperial Chemical Industries Plc||Amide derivatives|
|US5236957 *||May 25, 1990||Aug 17, 1993||Farmitalia Carlo Erba Srl||N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation|
|US5391577 *||May 25, 1993||Feb 21, 1995||Farmitalia Carlo Erba S R L||N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation|
|US5446066 *||Mar 22, 1994||Aug 29, 1995||Farmitalia Carlo Erba S.R.L.||Substituted (arylalkoxybenzyl)aminopropanamide derivatives and process for their preparation|
|US5449692 *||Mar 22, 1994||Sep 12, 1995||Farmitalia Carlo Erba S.R.L.||Substituted (arylalkylaminobenzyl) aminopropionamide derivatives and process for their preparation|
|US5475007||May 28, 1993||Dec 12, 1995||The Regents Of The University Of California||1,2,3,4-tetrahydroquinoline-2,3,4-trione-3 or 4-oximes and the use thereof|
|US5482964||Oct 11, 1994||Jan 9, 1996||Warner-Lambert Company||Substituted phenoxyhydroxypropyl amines as central nervous system agents|
|US5498610||Feb 1, 1994||Mar 12, 1996||Pfizer Inc.||Neuroprotective indolone and related derivatives|
|US5502079 *||Nov 17, 1994||Mar 26, 1996||Farmitalia Carlo Erba S.R.L.||N-phenylalkyl substituted α-amino carboxamide derivatives and process for their preparation|
|US5670546||Jan 11, 1996||Sep 23, 1997||Korean Research Institute Of Chemical Technology||N-Arylalkylphenylacetamide derivatives|
|US5688830||Jan 16, 1997||Nov 18, 1997||Syntex (U.S.A.) Inc.||Treatment of neuropathic pain|
|US5723489||May 7, 1996||Mar 3, 1998||Bristol-Myers Squibb Company||Aryloxypropanolamine beta 3 adrenergic agonists|
|US5741818||Jun 7, 1995||Apr 21, 1998||University Of Saskatchewan||Semicarbazones having CNS activity and pharmaceutical preparations containing same|
|US5849737||Apr 14, 1995||Dec 15, 1998||The Regents Of The University Of California||Compositions and methods for treating pain|
|US5945454||Jul 5, 1996||Aug 31, 1999||Pharmacia & Upjohn, S.P.A.||2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives|
|US6281211||Feb 4, 1999||Aug 28, 2001||Euro-Celtique S.A.||Substituted semicarbazides and the use thereof|
|US6303819 *||Dec 12, 1998||Oct 16, 2001||Newron Pharmaceuticals S.P.A.||Substituted 2-benzylamino-2-phenyl-acetamide compounds|
|US6479484||Nov 20, 1998||Nov 12, 2002||Euro-Celtique S.A.||Substituted 2-aminoacetamides and the use thereof|
|US6500825||Aug 21, 2001||Dec 31, 2002||Euro-Celtique S.A.||Substituted 2-aminoacetamides and the use thereof|
|US7091210||Dec 2, 2002||Aug 15, 2006||Purdue Neuroscience Company||Substituted 2-aminoacetamides and the use thereof|
|US20040248978||Aug 9, 2002||Dec 9, 2004||Patricia Salvati||Pharmaceutical composition comprising gabapentin or an analogue thereof and an aminoamide and its analgesic use|
|US20060079570||Nov 18, 2003||Apr 13, 2006||Patricia Salvati||Alpha-aminoamide derivatives useful as antimigraine agents|
|US20070093495||Apr 8, 2004||Apr 26, 2007||Fariello Ruggero||Methods for treatment of parkinson's disease|
|US20070203182||Apr 19, 2005||Aug 30, 2007||Claudia Besana||Alpha-Aminoamide Derivatives Useful In The Treatment Of Restless Legs Syndrome And Addictive Disorders|
|EP0200101A2||Apr 16, 1986||Nov 5, 1986||Usv Pharmaceutical Corporation||Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments|
|EP0415413A1||Aug 30, 1990||Mar 6, 1991||Warner-Lambert Company||Acat inhibitors|
|EP0525360A2||Jun 16, 1992||Feb 3, 1993||Korea Research Institute Of Chemical Technology||Novel phenylacetamide derivatives and processes for the preparation thereof|
|GB1140748A||Title not available|
|GB2059963A||Title not available|
|WO1990014334A1||May 25, 1990||Nov 29, 1990||Farmitalia Carlo Erba S.R.L.||N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION|
|WO1994022808A1||Mar 15, 1994||Oct 13, 1994||Farmitalia Carlo Erba Srl||Substituted (arylalkoxybenzyl)aminopropanamide derivatives, their preparation and use as anti-epileptic, neuroprotective and antidepressant agents|
|WO1994022809A1||Mar 15, 1994||Oct 13, 1994||Farmitalia Carlo Erba S.R.L.||Substituted (arylalkylaminobenzyl)aminopropionamide derivatives, their preparation and use anti-epileptic, neuroprotective and antidepressant agents|
|WO1996040628A1||Jun 7, 1996||Dec 19, 1996||The University Of Saskatchewan||Semicarbazones having cns activity and pharmaceutical preparations containing same|
|WO1997005102A1 *||Jul 5, 1996||Feb 13, 1997||Pharmacia & Upjohn S.P.A.||2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives|
|WO1997005111A1||Jul 5, 1996||Feb 13, 1997||Pharmacia & Upjohn S.P.A.||N-(4-substituted-benzyl)-2-aminolactam derivatives|
|WO1998019998A2||Nov 5, 1997||May 14, 1998||Novartis Ag||N-substituted 2-cyanopyrrolidines|
|WO1998043964A1||Mar 27, 1998||Oct 8, 1998||Newron Pharmaceuticals S.P.A.||2-[(3-substituted)-5-isoxazolylmethylamino]alkanamide derivatives|
|WO1998047869A1||Apr 22, 1998||Oct 29, 1998||Cocensys, Inc.||Carbocyclic and heterocyclic substituted semicarbazones and thiosemicarbazones and the use thereof|
|WO1999026614A1||Nov 20, 1998||Jun 3, 1999||Euro-Celtique S.A.||Substituted 2-aminoacetamides and the use thereof|
|WO1999039712A1||Feb 4, 1999||Aug 12, 1999||Euro-Celtique S.A.||Substituted semicarbazides and the use thereof|
|1||"Synthesis and Anticonvulsant Activity of a New Class of 2-(Arylalky) aminolalkanamide Derivatives", Pevarello et al, Journal of Medicinal Chemistry, vol. 41, No. 4, Feb. 12, 1998, pp. 579-590.|
|2||(First) Declaration of Robert A. McArthur, Pevarello Exhibit 2036, interference 105,394 (2006).|
|3||Anonymous, "Cambridge NeuroScience's grant for channel blockers," SCRIP World Pharmaceutical News 1870:8 (1993).|
|4||Anonymous, "Neurogen Licenses National Institutes of Health (NIH) anticonvulsants," SCRIP World Pharmaceutical News 1773:14 (1992).|
|5||Awouters (ed.), Proceedings, XIVth International Symposium on Medicinal Chemistry, Maastricht, The Netherlands, Sep. 8-12, 1996, Elsevier Science B.V. (Amsterdam), (cover, front matter, table of contents, index of authors, subject index, Stanford University Libraries date stamp). Copyright 1997; date stamped Aug. 24, 1998, Swain Library, Stanford University.|
|6||Bensimon, G., et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis," New Engl. J. Med. 330:585-591 (1994).|
|7||Brown, C.M., et al., "Neuroprotective properties of Lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia," British J. Pharmacol. 115:1425-1432 (1995).|
|8||Catterall, W.A., "Common modes of drug action on Na<SUP>+</SUP> channels: Local anesthetics, antiarrhythmics and anticonvulsants," Trends Pharmacol. Sci. 8:57-65 (1987).|
|9||Catterall, W.A., "Neurotoxins that Act on Voltage-Sensitive Sodium Channels in Excitable Membranes," Ann. Rev. Pharmacol. Toxicol. 20:15-43 (1980).|
|10||Catterall, W.A., "Structure and Function of Voltage-Sensitive Ion Channels," Science 242:50-61 (1988).|
|11||*||CDER Data Standards Manual [online], [retrieved on Jun. 20, 2007]. Retrieved from the Internet, URL <http://www.fda.gov/cder/dsm/DRG/drg00301.htm>.|
|12||Complaint, Civil Action No. 1:07-cv-00487 (Mar. 12, 2007).|
|13||Cover and bibliographic page, from Abstracts, Society for Neuroscience 26<SUP>th </SUP>Annual Meeting, Washington DC, Nov. 16-21, 1996, (2 pages) (Nov. 16, 1996, date solely for purpose of initial consideration).|
|14||Decision, Preliminary Motions, Bd.R. 125, interference No. 105,394 (2007).|
|15||Denicoff, K.D., et al., "Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey," J. Clin. Psychiatry 55:70-76 (1994).|
|16||Dimmock, J.R., et al., "(Aryloxy)aryl Semicarbazones and Related Compounds: A Novel Class of Anticonvulsant Agents Possessing High Activity in the Maximal Electroshock Screen," J. Med. Chem. 39:3984-3997 (1996).|
|17||Dostert et al., "New anticonvulsants with selective MAO-B inhibitory activity," European Neuropsychopharmacology, 1(3):317-319 (Sep. 1991).|
|18||Elrifi et al., "Request for ex parte reexamination of U.S. Patent No. 6,479,484 B1," filed Jul. 2, 2003.|
|19||Fariello et al., "Preclinical evaluation of PNU-151774E as a novel anticonvulsant," J. Pharmacol. Exp. Ther. 285(2):397-403 (May 1998).|
|20||Fields, "Peripheral neuropathic pain: an approach to management," in PD Wall and R Melack (eds.), Textbook of Pain, 3<SUP>rd </SUP>ed., Churchill Livingstone, pp. 991-996 (1994).|
|21||First Declaration of Stephen G. Waxman, M.D., Ph.D., PX 2003, interference No. 105,394 (2006).|
|22||Galer, BS, "Neuropathic pain of peripheral origin: advances in pharmacologic treatment," Neurol. 45:S17-S25, 1995.|
|23||Graham, S.H., et al., "Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion," J. Pharmacol. Exp. Ther. 269:854-859 (1994).|
|24||Guieu et al., "Central analgesic effect of valproate in patients with epilepsy," Seizure 2:147-150 (1993).|
|25||Hammer et al., "Effect of Riluzole on acute pain and hyperalgesia in humans," Brit. J. Anaesthesia 82(5):718-22 (1999).|
|26||Judgment, Preliminary Motions, Bd.R. 127, interference No. 105,394 (2007).|
|27||Kingery, "A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes," Pain 73:123-139 (1997).|
|28||Lunardi et al., "Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia," Neurology 48(6):1714-1717 (1997).|
|29||McQuay et al., "Anticonvulsant drugs for management of pain: a systematic review," BMJ 311:1047-1052 (Oct. 21, 1995).|
|30||Memorandum Opinion and Order, interference No. 105,394 (2007).|
|31||Nakamura-Craig et al., "Effect of lamotrigine in the acute and chronic hyperalgesia induced by PGE<SUB>2 </SUB>and in the chronic hyperalgesia in rats with streptozocin-induced diabetes," Pain 63:33-37 (1995).|
|32||*||New Riverside University Dictionary, The Riverside Publishing Company, Copyright 1984, 1988 and 1994, p. 845.|
|33||Notice Of Dismissal With Prejudice, Civil Action No. 1:07-cv-00487 (Jul. 25, 2007).|
|34||Official action, counterpart Brazilian application No. PI 9814548-7 (translation).|
|35||Pevarello et al., "Stereoselectivity, sigma binding and sodium channel blocking activity of 2-amino propanamide anticonvulsants." (3 pages) (Sep. 12, 1996).|
|36||Pevarello et al., "Stereoselectivity, sigma binding and sodium channel blocking activity of 2-aminopropanamide anticonvulsants," from Abstracts, XIVth International Symposium on Medicinal Chemistry, Maastricht, the Netherlands, Sep. 8-12, 1996 (4 pages) (Sep. 8, 1996).|
|37||Pevarello et al., "Synthesis and Anticonvulsant Activity of a New Class of 2-[(Arylalkyl)amino]alkanide Derivatives", J. Med. Chem. 41:579-590 (1998).|
|38||Puig et al., "Formalin-evoked activity in identified primary afferent fibers: systemic lidocaine suppresses phase-2 activity," Pain 64:345-355 (1995).|
|39||*||Route of administration [online], [retrieved on Jun. 20, 2007]. Retrieved from the Internet, URL<http://en.wikipedia.org/w/index.php?title-Route_of_administration&oldid=139095793>.|
|40||Salvati et al., "Anticonvulsant profile of FCE 26743A, a novel 2-aminopropionamide derivative," #825.16, from Abstracts, Society for Neuroscience 26<SUP>th </SUP>Annual Meeting, Washington DC, Nov. 16-21, 1996, (2 pages) (Nov. 16, 1996, date solely for purpose of initial consideration).|
|41||Salvati et al., "Anticonvulsant profile of FCE 26743A, a novel 2-aminopropionamide derivative," #825.16, from Abstracts, Society for Neuroscience 26<SUP>th </SUP>Annual Meeting, Washington DC, Nov. 16-21, 1996. (3 pages) (Nov. 16, 1996, date solely for purpose of initial consideration).|
|42||Salvati et al., "Anticonvulsant profile of FCE26743A (PNU-151774), a novel 2-aminopropionamide derivative. Society for Neuroscience. Washington. Nov. 15-21, 1996." (4 pages) (Nov. 21, 1996, date solely for purpose of initial consideration).|
|43||Shibata et al., "Modified formalin test: characteristic biphasic pain response," Pain 38:347-352 (1989).|
|44||Specification and claims as amended by (first) and second preliminary amendments, U.S. Appl. No. 11/574,751.|
|45||Specification and claims as amended by preliminary amendment, U.S. Appl. No. 10/569,403 (pending).|
|46||Specification and claims as amended by preliminary amendment, U.S. Appl. No. 10/586,494 (pending).|
|47||Stys, P.K., et al., "Ionic Mechanism of Anoxic Injury in Mammalian CNS White Matter: Role of Na<SUB>+</SUB> Channels and Na<SUP>+</SUP>-Ca<SUP>2+</SUP> Exchanger," J. Neurosci. 12:430-439 (1992).|
|48||Supplemental data, Vieth et al., "Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs," J. Med. Chem. 47:224-232 (2004) (downloaded Aug. 20, 2007 from http://pubs.acs.org) (excerpted fields).|
|49||Tanelian et al., "Neuropathic pain can be relieved by drugs that are use-dependent sodium channel blockers: lidocaine, carbamazepine, and mexiletine," Anesthesiol. 74(5):949-951 (1991).|
|50||Tanelian et al., "Sodium channel-blocking agents: their use in neuropathic pain conditions," Pain Forum 4(2):75-80 (1995).|
|51||Taylor, C.P. and Meldrum, B.S., "Na<SUP>+</SUP> channels as targets for neuroprotective drugs," Trends Pharmacol. Sci. 16:309-316 (1995).|
|52||Tjolsen et al., "The formalin test: an evaluation of the method," Pain 51:5-17 (1992).|
|53||Vaghi et al., "Neuroprotective effect of PNU-151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils," from Abstracts, Society for Neuroscience 27<SUP>th </SUP>Annual Meeting, New Orleans, LA, Oct. 25-30, 1997, (2 pages) (Oct. 25, 1997, date solely for purpose of initial consideration).|
|54||Vaghi et al., "Neuroprotective effect of PNU-151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils," from Abstracts, Society for Neuroscience, 27<SUP>th </SUP>Annual Meeting, New Orleans, LA, Oct. 25-30, 1997. (3 pages) (date stamped Apr. 26, 1999).|
|55||Vaghi et al., "Neuroprotective effect of PNU-151774E, a new anticonvulsant compound, in the model of global ischaemia in gerbils." (5 pages) (Oct. 30, 1997, date solely for purpose of initial consideration).|
|56||Varasi et al., "Synthesis and anticonvulsant activity of new benzyloxybenzylacetamide derivatives" (2 pages) (1992).|
|57||Varasi et al., "Synthesis and anticonvulsant activity of new benzyloxybenzylacetamide derivatives," from Abtracts, XII<SUP>th </SUP>International Symposium on Medicinal Chemistry, Basel, Switzerland, Sep. 13-17, 1992 (2 pages) (1992).|
|58||Vieth et al., "Characteristic Physical Properties and Structural Fragments of Marketed Oral Drugs," J. Med. Chem. 47:224-232 (2004).|
|59||Webber, "Observations under article 115 EPC", filed Nov. 19, 2002 in EP 98958114.5 (EP 1032377).|
|60||Wilton, "Tegretol in the treatment of diabetic neuropathy," S. Afr. Med. J. 48(20):869-872 (1974).|
|61||Woolf et al., "The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord," Pain 23(4):361-374 (1985).|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US7709523||Nov 18, 2003||May 4, 2010||Newron Pharmaceuticals Spa||Alpha-aminoamide derivatives useful as antimigraine agents|
|US7855227||Nov 29, 2006||Dec 21, 2010||Newron Pharmaceuticals S.P.A.||2-phenylethylamino derivatives as calcium and/or sodium channel modulators|
|US8084447||Aug 9, 2002||Dec 27, 2011||Newron Pharmaceuticals S.P.A.||Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use|
|US8129427||Sep 9, 2010||Mar 6, 2012||Newron Pharmaceuticals S.P.A.||2-phenylethylamino derivatives as calcium and/or sodium channel modulators|
|US8470877||Jan 26, 2012||Jun 25, 2013||Newron Pharmaceuticals S.P.A.||2-phenylethylamino derivatives as calcium and/or sodium channel modulators|
|US8710040||Dec 7, 2011||Apr 29, 2014||Newron Pharmaceuticals S.P.A.||Pharmaceutical composition comprising gabapentin or an analogue thereof and an α-aminoamide and its analgesic use|
|US20040248978 *||Aug 9, 2002||Dec 9, 2004||Patricia Salvati||Pharmaceutical composition comprising gabapentin or an analogue thereof and an aminoamide and its analgesic use|
|US20060079570 *||Nov 18, 2003||Apr 13, 2006||Patricia Salvati||Alpha-aminoamide derivatives useful as antimigraine agents|
|US20080096965 *||Jul 28, 2005||Apr 24, 2008||Newron Pharmaceuticals S.P.A.||(Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators|
|US20080319057 *||Nov 29, 2006||Dec 25, 2008||Newron Pharmaceuticals S.P.A.||2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators|
|US20100016440 *||Aug 20, 2009||Jan 21, 2010||Newron Pharmaceuticals S.P.A.||Alpha-aminoamide derivatives useful as anti-inflammatory agents|
|US20100267835 *||Jan 15, 2010||Oct 21, 2010||Newron Pharmaceuticals Spa||Methods of treating disorders of trigeminalvascular activation|
|US20110046129 *||Sep 9, 2010||Feb 24, 2011||Newron Pharmaceuticals S.P.A.||2-Phenylethylamino Derivatives as Calcium and/or Sodium Channel Modulators|
|US20110184068 *||Nov 4, 2010||Jul 28, 2011||Newron Pharmaceuticals S.P.A.||Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators|
|U.S. Classification||514/522, 564/164, 514/619, 564/171, 564/163, 558/414, 514/620|
|International Classification||C07C237/06, A61K31/165, A61K31/277, C07C255/50, C07C255/54, A61K31/275, C07C233/05, A61P25/04|
|Cooperative Classification||C07C237/06, A61K31/165, C07C255/54|
|European Classification||A61K31/165, C07C237/06, C07C255/54|
|Apr 23, 2009||FPAY||Fee payment|
Year of fee payment: 8
|Mar 14, 2013||FPAY||Fee payment|
Year of fee payment: 12